# Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

> **NCT04145258** · PHASE3 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 768 (estimated)

## Conditions studied

- Tuberculous Meningitis

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Placebo of aspirin
- **DRUG:** WHO TBM treatment
- **DRUG:** Intensified TBM treatment

## Key facts

- **NCT ID:** NCT04145258
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-07
- **Primary completion:** 2025-09
- **Final completion:** 2026-04
- **Target enrollment:** 768 (ESTIMATED)
- **Last updated:** 2024-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145258, "Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04145258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*